WO1993016069A1 - (alcoxy azaaromatique) indoles inhibiteurs de biosynthese de leucotriene - Google Patents
(alcoxy azaaromatique) indoles inhibiteurs de biosynthese de leucotriene Download PDFInfo
- Publication number
- WO1993016069A1 WO1993016069A1 PCT/CA1993/000059 CA9300059W WO9316069A1 WO 1993016069 A1 WO1993016069 A1 WO 1993016069A1 CA 9300059 W CA9300059 W CA 9300059W WO 9316069 A1 WO9316069 A1 WO 9316069A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- hydrogen
- pharmaceutically acceptable
- formula
- lower alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- European Patent Applications 166,591 and 275,667 disclose a series of indole-based compounds with activity as prostaglandin antagonists and inhibitors of leukotriene biosynthesis respectively.
- EP 181,568 and EP 200,101 are disclosed a series of compounds, containing two aromatic nuclei, which are described as possessing activity as lipoxygenase inhibitors.
- EP 279,263 is disclosed a series of indoles, benzofurans and benzothiophenes which are described as possessing activity as lipoxygenase
- U.S. Patent 4,629,733 describes novel indolinones which are antithrombotic and inhibit both phosphodiesterase and tumor metastasis.
- the chemical preparation of quinolylindoles is referred to by Sheinkman, et al . , Chem. Ab. , Vol. 67, 54017 (1967), without mentioning any utility for such compounds.
- a number of N-acyl derivatives of indole-3-acetic acid are described as potential anti-inflammatory agents by Biniecki, et al., Chem. Ab., Vol. 98, 197936
- EP 419,049 (March 27, 1991) teaches (quinolin-2-ylmethoxy)indoles as inhibitors of leukotriene biosynthesis.
- the present invention relates to compounds having activity as leukotriene biosynthesis
- inhibitors to methods for their preparation, and to methods and pharmaceutical formulations for using these compounds in mammals (especially humans).
- the compounds of the present invention are useful as anti-asthmatic, anti-allergic, and anti-inflammatory agents and are useful in treating allergic rhinitis and chronic bronchitis and for amelioration of skin diseases like psoriasis and atopic eczema. These compounds are also useful to inhibit the pathologic actions of leukotrienes on the cardiovascular and vascular systems for example, actions such as result in angina or endotoxin shock.
- the compounds of the present invention are useful in the treatment of inflammatory and allergic diseases of the eye, including allergic conjunctivitis.
- the compounds are also useful as cytoprotective agents and for the treatment of migraine headache.
- the compounds of the present invention may also be used to treat or prevent mammalian
- hepatic ischemia noxious agent-induced damage or necrosis of hepatic, pancreatic, renal, or myocardial tissue
- liver parenchymal damage caused by hepatoxic agents such as CCl 4 and D-galactosamine
- ischemic renal failure disease-induced hepatic damage
- bile salt induced pancreatic or gastric damage trauma- or stress-induced cell damage
- glycerol-induced renal failure glycerol-induced renal failure.
- the compounds of this invention are inhibitors of the biosynthesis of 5-lipoxygenase metabolites of arachidonic acid, such as 5-HPETE, 5-HETE and the leukotrienes.
- Leukotrienes B 4 , C 4 , D 4 and E 4 are known to contribute to various disease conditions such as asthma, psoriasis, pain, ulcers and systemic anaphylaxis. Thus inhibition of the synthesis of such compounds will alleviate these and other leukotriene-related disease states.
- the present invention provides novel compounds of the formula I:
- Het is ArR 1 R 2 R 3 ;
- Ar is a monocyclic aromatic 5- or 6-membered ring containing 1 to 3 N atoms, and the N-oxides thereof;
- R 1 , R 2 , R 3 , R 4 , R 5 , and R 11 are independently
- R 6 is hydrogen, -CH 3 , CF 3 , -C(O)H, X 1 - R 7 or X 2 -R 8 ;
- R 7 and R 10 are independently alkyl, alkenyl,
- R 9 is hydrogen or X 3 -R 10 ; each R 12 is independently hydrogen or lower alkyl, or two R 12 's on same carbon atom are joined to form a cycloalkyl ring of 3 to 6 carbon atoms ;
- R 13 is hydrogen, lower alkyl or -CH 2 R 22 ;
- R 14 is lower alkyl or -(CH 2 ) r R 22 ;
- R 15 is -CF 3 or R 14 ;
- R 16 is hydrogen, -COR 17 , R 14 , or two R 16 's on the same nitrogen may be joined to form a monocyclic heterocyclic ring of 4 to 6 atoms containing up to 2 heteroatoms chosen from O, S, or N;
- R 17 is hydrogen, -CF 3 , lower alkyl, lower alkenyl, lower alkynyl or -(CH 2 ) r R 22 ;
- R 18 is -(CH 2 ) S -C(R 19 R 19 )-(CH 2 ) s -R 20 or
- R 19 is hydrogen or lower alkyl
- SUBSTITUTE SHEET R 20 is a) a monocyclic or bicyclic heterocyclic ring containing from 3 to 9 nuclear carbon atoms and 1 or 2 nuclear
- hetero-atoms selected from N, S or O and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or b) the radical W-R 21 ;
- R 21 is alkyl or -COR 24 ;
- R 22 is phenyl substituted with 1 or 2 R 23 groups
- R 23 is hydrogen, halogen, lower alkyl, lower
- alkylsulfonyl lower alkylcarbonyl, -CF 3 ,
- R 24 is alkyl, cycloalkyl, or monocyclic
- R 25 is the residual structure of a standard amino acid, or R 19 and R 25 attached to the same N can cyclize to form a proline residue;
- R 26 is hydrogen or lower alkyl
- R 27 is lower alkyl or R 26 and R 27 on the same
- p is 0 to 3 when m is 0;
- r is 0 to 2;
- s is 0 to 3;
- t 0 to 2;
- u is 0 to 3;
- W is 0, S or NR 16
- X 1 is 0 or NR 16 ;
- X 2 is CO, CR 12 R 12 , S, S(O), or S(O) 2 ;
- X 3 is CO, CR 12 R 12 , S(O) 2 , or a bond;
- Y is X 1 or X 2 ;
- Y 1 is O, S, S(O) 2 , or CR 26 R 26 ;
- Q is -CO 2 R 13 , -CONHS(O) 2 R 15 , -NHS(O) 2 R 15 ,
- a preferred embodiment of Formula I is that in which X 4 is CHMe-O, and the remaining substituents are as defined for Formula I.
- R 1 , R 2 , R 3 , R 4 , and R 5 are hydrogen
- R 6 is X 2 -R 8 ;
- R 8 is R 7 ;
- R 9 is R 10 ;
- R 11 is hydrogen or halogen; m is 0;
- n 1 to 3;
- u is O in R 7 and 1 in R 10 ;
- X 2 is CR 12 R 12 or S
- X 4 is CR 26 R 27 -Y 1 ;
- Y 1 is 0
- Q is -CO 2 R 13 or 1-H or 2H-tetrazol-5-yl; and the remaining substituents are as defined for Formula I; or a pharmaceutically acceptable salt thereof.
- Ph phenyl
- DIBAL-N diisobutyl alumnium hydride
- HMPA hexamethylphosphorictriamide
- KHMDS potassium hexamethyldisilazide
- NBS N-bromosuccinimide
- NCS N-chlorosuccinimide
- Alkyl, alkenyl, and alkynyl are intended to include linear, branched, and cyclic structures and combinations thereof.
- Alkyl includes “lower alkyl” and extends to cover carbon fragments having up to 20 carbon atoms.
- alkyl groups include octyl, nonyl, norbornyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, eicosyl, 3,7-diethyl-2,2-dimethyl-4-propylnonyl, cyclododecyl, adamantyl, and the like.
- Lower alkyl means alkyl groups of from 1 to 7 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 2-methylcyclopropyl, cyclopropylmethyl, and the like.
- Cycloalkyl refers to a hydrocarbon ring having from 3 to 7 carbon atoms.
- cycloalkyl groups are cyclopropyl, cyclopentyl, cycloheptyl, and the like.
- “Lower alkenyl” means alkenyl groups of 2 to 7 carbon atoms. Examples of lower alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like. "Lower alkynyl” means alkynyl groups of 2 to 7 carbon atoms. Examples of lower alkynyl groups include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl, and the like.
- Lower alkoxy means alkoxy groups of from 1 to 7 carbon atoms of a straight, branched, or cyclic configuration. Examples of lower alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy,
- Lower alkylthio means alkylthio groups of from 1 to 7 carbon atoms of a straight, branched or cyclic configuration. Examples of lower alkylthio groups include methylthio, propylthio, isopropylthio, cycloheptylthio, etc. By way of illustration, the propylthio group signifies -SCH 2 CH 2 CH 3 .
- monocyclic monoheterocyclic ring which defines R 24 means monocyclic groups of 5 to 7 members containing only 1 heteroatom selected from N, S or O in the ring: Examples include tetrahydrofuran, tetrahydrothiophene, pyrrolidine, piperidine, tetrahydropyran, and the like.
- heterocyclic ring which defines R 20 may be
- “Monocyclic aromatic 5- or 6-membered ring containing 1 to 3 N atoms, and the N-oxides thereof" which defines “Ar” may include pyrrole, imidazole, 1,2,3-triazole, 1,2,4-triazole, pyridine, pyridazine, pyrimidine, pyrazine, 1,2,3-, 1,2,4-, or
- the point of attachment of any heterocyclic ring may be at any free valence of the ring.
- standard amino acid is employed to include the following amino acids: alanine,
- R 1 and R 2 may be located at any free positions of Ar .
- Ph(R 11 ) 2 and Th(R 11 ) 2 indicate a phenyl or thienyl group substituted with two R 11 substituents.
- Halogen includes F, Cl, Br, and I.
- -NR 16 R 16 represents -NHH, -NHCH 3 , -NHC 6 H 5 , etc.
- the monocyclic heterocyclic rings formed when two R 16 groups join through N include
- prodrug esters of Q are intended to include the esters such as are described by Saari et al., J. Med. Chem., 21, No. 8, 746-753 (1978), Sakamoto et al., Chem. Pharm.
- Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers.
- the present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof.
- compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a
- salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium andsodium salts.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine, caffeine, choline,
- salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
- acids include acetic,
- citric particularly preferred are citric,
- hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids.
- the ability of the compounds of Formula I to inhibit biosynthesis of the leukotrienes makes them useful for inhibiting the symptoms induced by the leukotrienes in a human subject.
- This inhibition of the mammalian biosynthesis of leukotrienes indicates that the compounds and pharmaceutical compositions thereof are useful to treat, prevent or ameliorate in mammals and especially in humans: 1) pulmonary conditions including diseases such as asthma, 2) allergies and allergic reactions such as allergic rhinitis, contact dermatitis, allergic
- conjunctivitis and the like, 3) inflammation such as arthritis or inflammatory bowel disease, 4) pain, 5) skin conditions such as psoriasis and the like, 6) cardiovascular conditions such as angina, endotoxin shock, and the like and 7) renal insufficiency arising from ischaemia induced by immunological or chemical (cyclosporin) etiology, and that the
- the cytoprotective activity of a compound may be observed in both animals and man by noting the increased resistance of the gastrointestinal mucosa to the noxious effects of strong irritants, for example, the ulcerogenic effects of aspirin or indomethacin.
- strong irritants for example, the ulcerogenic effects of aspirin or indomethacin.
- cytoprotective compounds will prevent gastric lesions induced by oral administration of strong acids, strong bases, ethanol, hypertonic saline solutions and the like.
- Two assays can be used to measure
- Formula I and its route of administration will also vary according to the age, weight and response of the individual patient.
- the daily dose range for anti-asthmatic, anti-allergic or anti-inflammatory use and generally, uses other than cytoprotection lie within the range of from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably 0.01 mg to about 10 mg per kg, and most preferably 0.1 to 1 mg per kg, in single or divided doses. On the other hand, it may be
- anti-allergic use is from about 0.001 mg to about 25 mg (preferably from 0.01 mg to about 1 mg) of a compound of Formula I per kg of body weight per day and for cytoprotective use from about 0.1 mg to about 100 mg (preferably from about 1 mg to about 100 mg and more preferably from about 1 mg to about 10 mg) of a compound of Formula I per kg of body weight per day.
- a suitable dosage range for anti-asthmatic, anti-inflammatory or anti-allergic use is, e.g. from about 0.01 mg to about 100 mg of a compound of
- Formula I per kg of body weight per day, preferably from about 0.1 mg to about 10 mg per kg and for cytoprotective use from 0.1 mg to about 100 mg
- ophthalmic preparations for ocular administration comprising 0.001-17o by weight solutions or
- suspensions of the compounds of Formula I in an acceptable ophthalmic formulation may be used.
- Formula I to be used as a cytoprotective agent will depend on, inter alia, whether it is being
- a compound of the Formula I administered to heal damaged cells or to avoid future damage, on the nature of the damaged cells (e.g., gastrointestinal ulcerations vs. nephrotic necrosis), and on the nature of the causative agent.
- An example of the use of a compound of the Formula I in avoiding future damage would be co-administration of a
- the compound of the Formula I with a non-steroidal anti-inflammatory drug (NSAID) that might otherwise cause such damage (for example, indomethacin).
- NSAID non-steroidal anti-inflammatory drug
- the compound of Formula I is administered from 30 minutes prior up to 30 minutes after
- NSAID a compound selected from the group consisting of NSAIDs, NSAIDs, and others.
- NSAID a combination dosage form
- Any suitable route of administration may be employed for providing a mammal, especially a human with an effective dosage of a compound of the present invention.
- oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed.
- Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
- compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
- pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including
- inorganic bases or acids and organic bases or acids are inorganic bases or acids and organic bases or acids.
- compositions include compositions suitable for oral, rectal, topical, parenteral
- the compounds of the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers.
- the compounds may also be delivered as powders which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device.
- the preferred delivery system for inhalation is a metered dose inhalation (MDI)
- aerosol which may be formulated as a suspension or solution of Compound I in suitable propellants, such as fluorocarbons or hydrocarbons.
- Suitable topical formulations of Compound I include transdermal devices, aerosols, creams, ointments, lotions, dusting powders, and the like.
- the compounds of Formula I can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
- a pharmaceutical carrier may take a wide variety of forms
- compositions for oral dosage form any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents,
- oral liquid preparations such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets, with the solid oral preparations being preferred over the liquid
- tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously
- the compounds of Formula I may also be administered by controlled release means and/or delivery devices such as those described in U.S.
- compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion.
- Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association the active ingredient with the carrier which
- compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
- a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
- each tablet contains from about 2.5 mg to about 500 mg of the active ingredient and each cachet or capsule contains from about 2.5 to about 500 mg of the active ingredient.
- compositions of the present invention can also contain other active ingredients, such as
- cyclooxygenase inhibitors include non-steroidal anti-inflammatory drugs (NSAIDs), peripheral analgesic agents such as zomepirac diflunisal and the like.
- NSAIDs non-steroidal anti-inflammatory drugs
- peripheral analgesic agents such as zomepirac diflunisal and the like.
- the weight ratio of the compound of the Formula I to the second active ingredient may be varied and will depend upon the
- the weight ratio of the compound of the Formula I to the NSAID will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200.
- Combinations of a compound of the Formula I and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.
- the propionic acid derivatives which may be used comprise: alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, pirprofen,
- anti-inflammatory properties are also intended to be included in this group.
- analgesics/non-steroidal anti-inflammatory drugs having a free -CH(CH 3 )COOH or -CH 2 CH 2 COOH group (which optionally can be in the form of a
- a carbonyl function typically attached directly or via a carbonyl function to a ring system, preferably to an aromatic ring system.
- the acetic acid derivatives which may be used comprise: indomethacin, which is a preferred NSAID, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin and zomepirac.
- Structually related acetic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.
- acetic acid derivatives as defined herein are non-narcotic analgesics/non-steroidal anti-inflammatory drugs having a free -CH 2 COOH group (which optionally can be in the form of a
- -CH 2 COO-Na + typically attached directly to a ring system, preferably to an aromatic or heteroaromatic ring system.
- fenamic acid derivatives which may be used comprise: flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid. Structurally related fenamic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.
- “fenamic acid derivatives” as defined herein are non-narcotic analgesics/non-steroidal anti-inflammatory drugs which contain the basic structure:
- the biphenylcarboxylic acid derivatives which can be used comprise: diflunisal and
- biphenylcarboxyli c acid derivatives as defined herein are non-narcotic
- analgesics/non-steroidal anti-inflammatory drugs which contain the basic structure:
- the oxicams which can be used in the present invention comprise: isoxicam, piroxicam, sudoxicam and tenoxican. Structurally related oxicams having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.
- oxicams as defined herein are non narcotic analgesics/non-steroidal anti-inflammatory drugs which have the general formula:
- R is an aryl or heteroaryl ring system
- NSAIDs may also be used:
- benzydanine beprozin, broperamole, bufezolac, cinmetacin, ciproquazone, cloximate, dazidamine, deboxamet, delmetacin, detomidine, dexindoprofen, diacerein, di-fisalamine, difenpyramide, emorfazone, enfenamic acid, enolicam, epirizole, etersalate, etodolac, etofenamate, fanetizole mesylate,
- fenclorac fendosal, fenflumizole, feprazone, floctafenine, flunixin, flunoxaprofen, fluproquazone, fopirtoline, fosfosal, furcloprofen, glucametacin, guaimesal, ibuproxam, isofezolac, isonixim,
- isoprofen isoxicam, lefetamine HCl, leflunomide, lofemizole, lonazolac calcium, lotifazole,
- loxoprofen lysin clonixinate, meclofenamate sodium, meseclazone, nabumetone, nictindole, nimesulide, orpanoxin, oxametacin, oxapadol, perisoxal citrate, pimeprofen, pimetacin, piproxen, pirazolac,
- pirfenidone proglumetacin maleate, proquazone, pyridoxiprofen, sudoxicam, talmetacin, talniflumate, tenoxicam, thiazolinobutazone, thielavin B, tiaramide HCl, tiflamizole, timegadine, tolpadol, tryptamid and ufenamate.
- NSAIDs designated by company code number (see e.g., Pharmaprojects), may also be used:
- NSAIDs which may also be used include the salicylates, specifically acetyl salicylic acid and the phenylbutazones, and pharmaceutically
- NSAIDS are acetyl salicylic acid, diclofenac, fenbufen, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, naproxen, phenylbutazone, piroxicam, sulindac and tolmetin.
- compositions comprising the Formula I compounds may also contain inhibitors of the biosynthesis of the leukotrienes such as are disclosed in EP 138,481 (April 24,1985), EP 115,394 (August 8, 1984), EP 136,893 (April 10, 1985), and EP 140,709 (May 8, 1985), which are hereby incorporated herein by reference.
- the compounds of the Formula I may also be used in combination with leukotriene antagonists such as those disclosed in EP 106,565 (April 25, 1984) and EP 104,885 (April 4, 1984) which are hereby
- compositions comprising the Formula I compounds may also contain as the second active ingredient, prostaglandin antagonists such as those disclosed in EP 11,067 (May 28, 1980) or thromboxane antagonists such as those disclosed in U.S. Pat. 4,237,160. They may also contain histidine decarboxylase inhibitors such as ⁇ -fluoromethylhistidine, described in U.S. Pat. 4,325,961.
- prostaglandin antagonists such as those disclosed in EP 11,067 (May 28, 1980) or thromboxane antagonists such as those disclosed in U.S. Pat. 4,237,160. They may also contain histidine decarboxylase inhibitors such as ⁇ -fluoromethylhistidine, described in U.S. Pat. 4,325,961.
- the compounds of the Formula I may also be advantageously combined with an H 1 - or H 2 -receptor antagonist, such as for instance acetamazole, aminothiadiazoles disclosed in EP 40,696 (December 2, 1981), benadryl
- compositions may also contain a K + /H + ATPase inhibitor such as omeprazole, disclosed in U.S. Pat. 4,255,431, and the like.
- K + /H + ATPase inhibitor such as omeprazole, disclosed in U.S. Pat. 4,255,431, and the like.
- Compounds of Formula I may also be usefully combined with most cell stabilizing agents, such as 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane and related
- composition comprises the Formula I compounds in combination with serotonin antagonists such as methysergide, the serotonin antagonists described in Nature, Vol. 316, pages 126-131, 1985, and the like.
- serotonin antagonists such as methysergide, the serotonin antagonists described in Nature, Vol. 316, pages 126-131, 1985, and the like.
- compositions comprise the Formula I compounds in combination with anti-cholinergics such as
- bronchodilators such as the beta agonist salbutamol, metaproterenol, terbutaline, fenoterol and the like, and the anti-asthmatic drugs theophylline, choline theophyllinate and
- enprofylline the calcium antagonists nifedipine, diltiazem, nitrendipine, verapamil, nimodipine, felodipine, etc. and the corticosteroids,
- hydrocortisone hydrocortisone, methylprednisolone, betamethasone, dexamethasone, beclomethasone, and the like.
- Temperatures are in degrees Celsius.
- the -CO 2 H and -CO 2 R 13 groups in the intermediates and final products in the various methods can be transformed to other representatives of Q such as -CONHS(O) 2 R 15 , -NHS(O) 2 R 15 , -CONR 16 R 16 , -CH 2 OH or tetrazol-5-yl by the methodology described in U.S. Patent 4,808,608 (17323IB).
- the preparation of the pro-drug forms (Q is -CO 2 R 18 ) from the acids may be effected by the methodology of EP 104,885 (16830 IA). It will be apparent to one skilled in the art that the various functional groups (R 1 , R 2 , Y, Q, etc.) must be chosen so as to be compatible with the chemistry being carried out. Such compatibility can often be achieved by protecting groups, or by
- the corresponding sulfoxides and sulfones can be prepared by oxidation of the sulfides with one or two equivalents of an oxidizing agent such as m-chloroperbenzoic acid or monoperoxyphthalic acid or oxone (Trost, J. Org.
- the carboxy derivative 1 may be reacted with an alkyl lithium reagent (R 27 Li) followed by a suitable hydride reducing agent such as lithium aluminum hydride, sodium borohydride, DIBAL-H, or the like, or by a second alkyl lithium reagent (R 26 Li) in appropriate solvents such as ether, THF, hexane, toluene, or mixtures thereof, to obtain alcohol 2 .
- the alcohol function of 2 can be converted to a suitable leaving group (LG) such as a halide, or a sulfonate ester (mesylate, tosylate, triflate, etc.) by methods well known in the art to produce
- LG suitable leaving group
- a useful subgroup of 3 can be prepared by halogenation of the alkyl compound
- Het-alkyl by heating with halogenating agents such as NCS or NBS in appropriate solvents such as carbon tetrachloride, benzene, and the like.
- Compound 4 is converted into the ylid 5 by treating with a base such as Et 3 N, sodium hydride, butyl lithium, or an alkoxide, depending upon the reactivity of the phosphonium salt 4.
- a base such as Et 3 N, sodium hydride, butyl lithium, or an alkoxide, depending upon the reactivity of the phosphonium salt 4.
- N-acetylated aminophenol XXVI is reacted with 3 using an alkali hydride or carbonate, such as potassium carbonate as a base in a polar solvent like DMF or NMP.
- alkali hydride or carbonate such as potassium carbonate as a base in a polar solvent like DMF or NMP.
- the resulting acetanilide 7 is then de-acetylated using standard basic
- the hydrazine 9 is then processed using a Fischer indolization with ketone IV to produce compound 10, which is then alkylated on the indole nitrogen using R 9 -Hal and a suitable base such as KHMDS in THF or NaH in DMF to give compound 11.
- sulfonic anhydride Tf 2 O
- a solvent like pyridine in dichloromethane Tf 2 O
- the phenol triflate may be carboxymethylated to a compound like 13 under
- phosphine ligand like 1,1-bis(diphenylphosphinoferrocene) enhances this reaction.
- Reduction of the carboxymethylated indole may be effected with a variety of hydride reducing agents.
- DIBAL-H is used in THF on the
- the reduced carbinol product 14 is conveniently oxidized to a formylated derivative 15 with manganese dioxide in methylene chloride as a typical solvent.
- Aldehyde 15 can then be homologated under carbanion conditions, typically using Wittig reagent 5 as shown in the method, under anydrous conditions in an etherial solvent like THF.
- the temperature of this reaction is typically from -70oC to room temperature.
- Indole styryl analogues 16 are thus formed. Further transformation of the styryl system may be effected by catalytic reduction using
- Indole thio analogues of I such as 23 and 24 are conveniently prepared by the sequence shown in Method 5.
- the treatment of compound V with BBr 3 in a chlorinated solvent such as CH 2 Cl 2 cleaves both the methyl ether and the indole N-benzyl group and
- N,N-dimethylcarbamoylthioindole derivative 20 rearrangement at >200°C gives rise to an N,N-dimethylcarbamoylthioindole derivative 20.
- the hydrolysis of 20 may be effected using strong base, typically sodium
- Hydrazine 9 may also be transformed directly to unsubstituted indoles by a Fischer reaction with various ketones like XXXI .
- N-Alkylation of the indoles is effected using the conditions described in Method 3 to produce hetmethoxyindole alkanoate esters 25.
- esters are transformed to ketones or carbinols via Grignard conditions using alkyl
- the carbinols 27 so produced may be further transformed into ester compounds of the present invention by reacting with halo esters XXXV using sodium hydride as base in a suitable solvent like THF. Subsequent hydrolysis of the esters leads to acid compounds 28. of the present invention.
- Table I illustrates compounds representative of the present invention.
- Compounds of Formula I can be tested using the following assays to determine their mammalian leukotriene biosynthesis inhibiting activity.
- Rats under ether anesthesia are injected (i.p.) with 8 mL of a suspension of sodium caseinate (6 grams in ca . 50 mL water). After 15-24 hr. the rats are sacrificed (CO 2 ) and the cells from the peritoneal cavity are recovered by lavage with 20 mL of buffer (Eagles MEM containing 30 mM HEPES adjusted to pH 7.4 with NaOH). The cells are pelleted (350 ⁇ g, 5 min.), resuspended in buffer with vigorous shaking, filtered through lens paper, recentrifuged and finally suspended in buffer at a concentration of 10 cells/mL.
- buffer Eagles MEM containing 30 mM HEPES adjusted to pH 7.4 with NaOH
- PMN Preparation of Human PMN.
- Human blood is obtained by antecubital venepuncture from consenting volunteers who have not taken medication within the previous 7 days. The blood is immediately added to 10% (v/v) trisodium citrate (0.13 M) or 5% (v/v) sodium heparin (1000 IU/mL).
- PMNs are isolated from anticoagulated blood by dextran sedimentation of erythrocytes followed by centrifugation through
- Ficoll-Hypaque (specific gravity 1.077), as described by Boyum (Scand. J. Clin. Lab. Invest., 21 (Supp.
- Contaminating erythrocytes are removed by lysis following exposure to ammonium chloride (0.16 M) in Tris buffer (pH 7.65), and the PMNs resuspended at 5 ⁇ 10 5 cells/mL in HEPES (15 mM)-buffered Hanks balanced salt solution containing Ca 2+ (1.4 mM) and Mg 2+ (0.7 mM), pH 7.4. Viability is assessed by Trypan blue exclusion.
- ionophore A23187 final concentration 10 mM or vehicle in control samples and allowed to proceed for 5 minutes at 37°C.
- the reactions are then terminated by the addition of cold methanol (0.25 mL) and samples of the entire PMN reaction mixture removed for radioimmunoassay of LTB 4 .
- Samples (50 mL) of authentic LTB 4 of known concentration in radioimmunoassay buffer (RIA) buffer (potassium phosphate 1 mM; disodium EDTA 0.1 mM;
- Inhibitory dose-response curves are constructed using a four-parameter algorithm and from these the IC 50 values are determined.
- Rats are obtained from an inbred line of asthmatic rats. Both female (190-250 g) and male (260-400 g) rats are used. Egg albumin (EA), grade V, crystallized and lyophilized, is obtained from Sigma Chemical Co., St. Louis. Aluminum hydroxide is obtained from the Regis Chemical Company, Chicago. Methysergide bimaleate is supplied by Sandoz Ltd., Basel.
- EA Egg albumin
- Aluminum hydroxide is obtained from the Regis Chemical Company, Chicago.
- Methysergide bimaleate is supplied by Sandoz Ltd., Basel.
- recordings are carried out in a clear plastic box with internal dimensions 10 ⁇ 6 ⁇ 4 inches.
- the top of the box is removable; in use, it is held firmly in place by four clamps and an airtight seal is
- nebulizer No. 40 is inserted via an airtight seal and each end of the box also has an outlet.
- Fleisch No. 0000 pneumotachograph is inserted into one end of the box and coupled to a Grass volumetric pressure transducer (PT5-A) which is then connected to a Beckman Type R Dynograph through appropriate couplers. While aerosolizing the antigen, the outlets are open and the pneumotachograph is isolated from the chamber. The outlets are closed and the pneumotachograph and the chamber are connected during the recording of the respiratory patterns. For challenge, 2 mL of a 3% solution of antigen in saline is placed into each nebulizer and the aerosol is generated with air from a small Potter diaphragm pump operating at 10 psi and a flow of 8 liters/minute.
- PT5-A Grass volumetric pressure transducer
- Rats are then exposed to an aerosol of 3% EA in saline for exactly 1 minute, then their respiratory profiles are recorded for a further 30 minutes. The duration of continuous dyspnea is measured from the respiratory recordings.
- Compounds are generally administered either orally 1-4 hours prior to challenge or intravenously 2 minutes prior to challenge. They are either dissolved in saline or 1% methocel or suspended in 1% methocel. The volume injected is 1 mL/kg
- Step A in DMF (450 mL) was added slowly. The mixture was slowly heated to 150oC and kept at that temperature for 18 hours. After cooling to room temperature, the supernatant layer was decanted and the residue dissolved in H 2 O and
- Step B Methyl 3-[N-(p-chlorobenzyl)-3-(t-butylthio- 5-[1-(pyridin-2-yl]ethoxy)indol-2-yl]-2,2- dimethylpropanoate
- Step C (689 mg) and stirred at 70°C for 2 hr. After the solution had cooled, it was poured onto 100 mL of NH 4 OAC (25% solution), extracted with 3x 50 mL of ethyl acetate, washed with 50 mL of brine, and dried over MgSO 4 . The solution was evaporated to dryness and the residue was
- the compound (594 mg) from Step B was hydrolyzed by dissolving it in 16 mL of THF, 8 mL of MeOH, and 4 mL of 1.0M LiOH.
- the solution was heated at 70oC for 2 hr.
- the solution was diluted with 50 mL of H 2 O, acidified with glacial AcOH to pH 5 and then diluted with 50 ml of NH4OAC (25% solution).
- the mixture was extracted with 3x 50 mL of EtOAc.
- the organic layer was washed with (1x 50 mL of brine, and dried over MgSO 4 .
- the solution was evaporated to dryness and coevaporated with 50 mL of toluene to provide the title acid as a foam.
- the title product was prepared as follows: the acid was suspended in ethanol (3 mL) and treated with 1.0N NaOH (1
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Des composés selon la formule (I) sont des inhibiteurs de biosynthèse de leucotriène. Ces composés sont utiles en tant qu'agents antiasthmatiques, antiallergiques, anti-inflammatoires et cytoprotecteurs. Ils sont également utiles dans le traitement de la diarrhée, de l'hypertension, de l'angine, de l'agrégation de plaquettes sanguines, du spasme cérébral, du travail prématuré, de l'avortement spontané, de la dysménorrhée et de la migraine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83491892A | 1992-02-13 | 1992-02-13 | |
US834,918 | 1992-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993016069A1 true WO1993016069A1 (fr) | 1993-08-19 |
Family
ID=25268134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1993/000059 WO1993016069A1 (fr) | 1992-02-13 | 1993-02-12 | (alcoxy azaaromatique) indoles inhibiteurs de biosynthese de leucotriene |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3488693A (fr) |
CA (1) | CA2129429A1 (fr) |
WO (1) | WO1993016069A1 (fr) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5952362A (en) * | 1997-06-23 | 1999-09-14 | Syntex (U.S.A) Inc. | 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of methylphenyl, methoxyphenyl, and aminophenyl alkylsulfonamides and ureas and their use |
US6291507B1 (en) | 1998-02-17 | 2001-09-18 | Astrazeneca Uk Limited | Chemical compounds |
US6441004B1 (en) | 1997-08-07 | 2002-08-27 | Zeneca Limited | Monocyte chemoattractant protein-1 inhibitor compounds |
US6569888B1 (en) | 1999-02-05 | 2003-05-27 | Astrazeneca Ab | Anti-inflammatory indole derivatives |
US6613760B1 (en) | 1999-02-05 | 2003-09-02 | Astrazeneca Ab | Indole derivatives and their use as MCP-1 receptor antagonists |
US6737435B1 (en) | 1999-02-05 | 2004-05-18 | Astrazeneca Ab | Indole derivatives and their use as MCP-1 antagonist |
EP1143972A4 (fr) * | 1998-10-13 | 2004-07-28 | Fred D Sheftell | Prevention et traitement de migraines et autres cephalees recurrentes au moyen de medicaments inhibant le recepteur de leucotriene d4 |
US6833387B1 (en) | 1999-02-05 | 2004-12-21 | Astrazeneca Ab | Chemical compounds |
US6911465B1 (en) | 1999-02-05 | 2005-06-28 | Astrazeneca Ab | Anti-inflammatory indole derivatives |
US6984657B1 (en) | 2000-01-13 | 2006-01-10 | Astrazeneca Ab | Indole derivatives as MCP-1 receptor antagonists |
WO2008137805A1 (fr) * | 2007-05-07 | 2008-11-13 | Amira Pharmaceuticals, Inc. | Inhibiteurs de protéine flap (5-lipoxygenase-activating protein) |
WO2008137609A1 (fr) * | 2007-05-04 | 2008-11-13 | Amira Pharmaceuticals, Inc. | Inhibiteurs de protéine flap (5-lipoxygenase-activating protein) |
WO2008141011A1 (fr) * | 2007-05-08 | 2008-11-20 | Amira Pharmaceuticals, Inc. | Inhibiteurs de protéine d'activation de la 5-lipoxygénase (flap) |
JP2009514959A (ja) * | 2005-11-04 | 2009-04-09 | アミラ ファーマシューティカルス,インコーポレーテッド | 5−リポキシゲナーゼ活性化タンパク質(flap)阻害剤 |
US7645752B2 (en) | 2006-01-13 | 2010-01-12 | Wyeth Llc | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors |
EP1943219A4 (fr) * | 2005-11-04 | 2010-06-02 | Amira Pharmaceuticals Inc | Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap) |
US7741326B2 (en) | 2006-11-09 | 2010-06-22 | Roche Palo Alto Llc | Indole and benzofuran 2-carboxamide derivatives and uses thereof |
US10080748B2 (en) | 2014-02-04 | 2018-09-25 | Bioscience Pharma Partners, Llc | Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0166591A2 (fr) * | 1984-06-25 | 1986-01-02 | Merck Frosst Canada Inc. | Acides indole-2-alcanoiques et leur utilisation comme antagonistes de prostaglandine |
EP0181568A2 (fr) * | 1984-10-30 | 1986-05-21 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Composés anti-inflammatoires/antiallergiques |
EP0419049A1 (fr) * | 1989-08-22 | 1991-03-27 | Merck Frosst Canada Inc. | (Quinoléine-2-ylméthoxy)-indoles comme inhibiteurs de la biosynthèse leucotriénique |
WO1991006537A2 (fr) * | 1989-10-27 | 1991-05-16 | American Home Products Corporation | Derives d'acide alcanoique indole, indene, pyranoindole et tetrahydrocarbazole substitues utilises comme inhibiteurs de la phospholipase a2 (pla2) et de la lipoxygenase |
WO1992003132A1 (fr) * | 1990-08-20 | 1992-03-05 | Abbott Laboratories | Derives d'indole inhibant la biosynthese de leucotriene |
-
1993
- 1993-02-12 WO PCT/CA1993/000059 patent/WO1993016069A1/fr active Application Filing
- 1993-02-12 AU AU34886/93A patent/AU3488693A/en not_active Abandoned
- 1993-02-12 CA CA002129429A patent/CA2129429A1/fr not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0166591A2 (fr) * | 1984-06-25 | 1986-01-02 | Merck Frosst Canada Inc. | Acides indole-2-alcanoiques et leur utilisation comme antagonistes de prostaglandine |
EP0181568A2 (fr) * | 1984-10-30 | 1986-05-21 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Composés anti-inflammatoires/antiallergiques |
EP0419049A1 (fr) * | 1989-08-22 | 1991-03-27 | Merck Frosst Canada Inc. | (Quinoléine-2-ylméthoxy)-indoles comme inhibiteurs de la biosynthèse leucotriénique |
WO1991006537A2 (fr) * | 1989-10-27 | 1991-05-16 | American Home Products Corporation | Derives d'acide alcanoique indole, indene, pyranoindole et tetrahydrocarbazole substitues utilises comme inhibiteurs de la phospholipase a2 (pla2) et de la lipoxygenase |
WO1992003132A1 (fr) * | 1990-08-20 | 1992-03-05 | Abbott Laboratories | Derives d'indole inhibant la biosynthese de leucotriene |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5952362A (en) * | 1997-06-23 | 1999-09-14 | Syntex (U.S.A) Inc. | 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of methylphenyl, methoxyphenyl, and aminophenyl alkylsulfonamides and ureas and their use |
US6057349A (en) * | 1997-06-23 | 2000-05-02 | F. Hoffman La Roche Ag | 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of methylphenyl, methoxphenyl, and aminophenyl alkylsulfonamides and ureas and their use |
US6441004B1 (en) | 1997-08-07 | 2002-08-27 | Zeneca Limited | Monocyte chemoattractant protein-1 inhibitor compounds |
US6953809B2 (en) | 1997-08-07 | 2005-10-11 | Zeneca Limited | Monocyte chemoattractant protein-1 inhibitor compounds |
US6291507B1 (en) | 1998-02-17 | 2001-09-18 | Astrazeneca Uk Limited | Chemical compounds |
EP1143972A4 (fr) * | 1998-10-13 | 2004-07-28 | Fred D Sheftell | Prevention et traitement de migraines et autres cephalees recurrentes au moyen de medicaments inhibant le recepteur de leucotriene d4 |
US6569888B1 (en) | 1999-02-05 | 2003-05-27 | Astrazeneca Ab | Anti-inflammatory indole derivatives |
US6613760B1 (en) | 1999-02-05 | 2003-09-02 | Astrazeneca Ab | Indole derivatives and their use as MCP-1 receptor antagonists |
US6737435B1 (en) | 1999-02-05 | 2004-05-18 | Astrazeneca Ab | Indole derivatives and their use as MCP-1 antagonist |
US6833387B1 (en) | 1999-02-05 | 2004-12-21 | Astrazeneca Ab | Chemical compounds |
US6911465B1 (en) | 1999-02-05 | 2005-06-28 | Astrazeneca Ab | Anti-inflammatory indole derivatives |
US6984657B1 (en) | 2000-01-13 | 2006-01-10 | Astrazeneca Ab | Indole derivatives as MCP-1 receptor antagonists |
US7834037B2 (en) | 2005-11-04 | 2010-11-16 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
EP2404904A1 (fr) * | 2005-11-04 | 2012-01-11 | Amira Pharmaceuticals, Inc. | Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (FLAP) |
NO342361B1 (no) * | 2005-11-04 | 2018-05-14 | Amira Pharmaceuticals Inc | 3-[3-tert-butylsulfanyl-1-[4-(6-etoksy-pyridin-3-yl)-benzyl]-5-(5-metyl-pyridin-2-ylmetoksy)-1H-indol-2-yl]-2,2-dimetyl-propionsyre, farmasøytisk preparat omfattende slike, kombinasjoner omfattende slike, anvendelse av slike som medikament og anvendelse av slike for behandling av sykdom |
JP2009514959A (ja) * | 2005-11-04 | 2009-04-09 | アミラ ファーマシューティカルス,インコーポレーテッド | 5−リポキシゲナーゼ活性化タンパク質(flap)阻害剤 |
EP1943219A4 (fr) * | 2005-11-04 | 2010-06-02 | Amira Pharmaceuticals Inc | Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap) |
EP1943266A4 (fr) * | 2005-11-04 | 2010-06-02 | Amira Pharmaceuticals Inc | Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap) |
US8841295B2 (en) | 2005-11-04 | 2014-09-23 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US8710081B2 (en) | 2005-11-04 | 2014-04-29 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
US7645752B2 (en) | 2006-01-13 | 2010-01-12 | Wyeth Llc | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors |
US7741326B2 (en) | 2006-11-09 | 2010-06-22 | Roche Palo Alto Llc | Indole and benzofuran 2-carboxamide derivatives and uses thereof |
EA017150B9 (ru) * | 2007-05-04 | 2013-03-29 | ПАНМИРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Ингибиторы белка, активирующего 5-липоксигеназу (flap) |
EA017150B1 (ru) * | 2007-05-04 | 2012-10-30 | ПАНМИРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Ингибиторы белка, активирующего 5-липоксигеназу (flap) |
WO2008137609A1 (fr) * | 2007-05-04 | 2008-11-13 | Amira Pharmaceuticals, Inc. | Inhibiteurs de protéine flap (5-lipoxygenase-activating protein) |
AU2008247672B2 (en) * | 2007-05-04 | 2013-04-11 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
JP2010526095A (ja) * | 2007-05-04 | 2010-07-29 | アミラ ファーマシューティカルス,インコーポレーテッド | 5−リポキシゲナーゼ活性化タンパク質(flap)阻害剤 |
WO2008137805A1 (fr) * | 2007-05-07 | 2008-11-13 | Amira Pharmaceuticals, Inc. | Inhibiteurs de protéine flap (5-lipoxygenase-activating protein) |
WO2008141011A1 (fr) * | 2007-05-08 | 2008-11-20 | Amira Pharmaceuticals, Inc. | Inhibiteurs de protéine d'activation de la 5-lipoxygénase (flap) |
US10080748B2 (en) | 2014-02-04 | 2018-09-25 | Bioscience Pharma Partners, Llc | Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system |
Also Published As
Publication number | Publication date |
---|---|
CA2129429A1 (fr) | 1993-08-14 |
AU3488693A (en) | 1993-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5290798A (en) | (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis | |
US5334719A (en) | Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis | |
US5190968A (en) | (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis | |
US5308850A (en) | (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis | |
US5389650A (en) | (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis | |
CA2079374C (fr) | Indol (azaarylmethoxy bicyclique) comme inhibiteur de leucotriene biosynthetique | |
US5273980A (en) | Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene biosynthesis | |
EP0419049B1 (fr) | (Quinoléine-2-ylméthoxy)-indoles comme inhibiteurs de la biosynthèse leucotriénique | |
US5380850A (en) | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes | |
US5221678A (en) | (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes | |
US5093356A (en) | Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase | |
WO1993016069A1 (fr) | (alcoxy azaaromatique) indoles inhibiteurs de biosynthese de leucotriene | |
US5187180A (en) | (quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes | |
US5204344A (en) | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes | |
US5314898A (en) | Aryl thiopyrano[4,3,2-cd]indoles as inhibitors of leukotriene biosynthesis | |
US5252585A (en) | Fluorinated quinoline indoles as inhibitors of the biosynthesis of leukotrienes | |
US5132319A (en) | 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis | |
US5036067A (en) | Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase | |
CA2136241C (fr) | Indoles a base de quinoleines fluores en tant qu'inhibiteurs de la biosynthese de leucotrienes | |
US5334597A (en) | Indole carbamates as leukotriene antagonists | |
CA1337427C (fr) | (quinoleine-2-ylmethoxy)indoles utilises en tant qu'inhibiteurs de la biosynthese des leucotrienes | |
CA2060557C (fr) | (quinolein-2-ylmethoxy)indoles, inhibiteurs de la biosynthese de leucotrienes | |
CA2079373C (fr) | Indol (azaarylmethoxy) comme inhibiteur de leucotriene biosynthetique | |
CA2007786C (fr) | Acides indenylhydroxamique et hydroxy urees comme inhibiteurs de la 5-lipoxygenase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA CZ FI HU JP KR LK MG MN MW NO NZ PL RO RU SD SK UA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2129429 Country of ref document: CA |
|
122 | Ep: pct application non-entry in european phase |